ZTEKF Stock Chart & Stats
$0.60
$0.04(6.88%)
At close: 4:00 PM EDT
$0.60
$0.04(6.88%)
Day’s Range― - ―
52-Week Range$0.37 - $1.10
Previous Close$0.59
VolumeN/A
Average Volume (3M)177.82K
Market Cap
$64.87M
Enterprise Value$60.34
Total Cash (Recent Filing)$16.60M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume299,526
30 Day Avg. Volume177,818
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageModest leverage and a meaningful equity base reduce refinancing and solvency pressure while giving Zentek some capacity to continue investing in technology commercialization. This financial cushion is a durable offset to operating weakness, although it does not eliminate the need to control losses.
Government Commercialization TractionA federal standing offer provides external validation for ZenGUARD HVAC filters and creates a defined route to potential government sales through 2027. While the stated maximum is modest, the arrangement can support customer credibility and future adoption of Zentek’s materials technology.
Expanding Intellectual Property PipelineA new provisional patent filing strengthens Zentek’s intellectual-property pipeline and broadens its potential application set beyond existing filtration and coating efforts. Protectable technology can support future licensing, partnerships, and differentiated commercialization if technical validation and market adoption follow.
Bears Say
Very Small, Declining RevenueExtremely low and declining revenue indicates that Zentek has not yet converted its research and product portfolio into repeatable commercial scale. Until sales growth becomes sustained, fixed development costs will remain difficult to absorb and the business will have limited internal funding capacity.
Persistent UnprofitabilityRepeated losses and deeply negative operating results show that Zentek’s current business model has not reached economic breakeven. The brief period of positive annual gross profit in 2025 did not establish stable margins, leaving profitability dependent on stronger commercialization and revenue growth.
Ongoing Cash BurnConsistently negative operating and free cash flow means current activities consume cash rather than fund themselves. Continued burn can reduce the company’s financial cushion over time and may constrain investment in product development or require additional financing if commercialization does not accelerate.
ZTEKF FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was $0.37 and its highest was $1.10 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is $64.87M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Nov 16, 2026 which is in 64 days.
How were Zentek’s earnings last quarter?
Currently, no data Available
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in ZTEKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 154.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $45.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―
Ownership Overview
1.58% Insiders
0.04% Mutual Funds
2.11% Other Institutional Investors
96.27% Public Companies and
Individual Investors